Crossmark

Anti-inflammatory and anti-COVID-19 effect of a novel polyherbal formulation (Imusil) via modulating oxidative stress, inflammatory mediators and cytokine storm

Crossref DOI link: https://doi.org/10.1007/s10787-021-00911-x

Published Online: 2022-01-25

Published Print: 2022-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ratheesh, M. https://orcid.org/0000-0002-4638-1633
Sunil, Sujatha

Sheethal, S.

Jose, Svenia P.

Sandya, S.

Ghosh, Oriparambil Sivaraman Nirmal

Rajan, Sony

Jagmag, Tariq

Tilwani, Jayesh
License Information

Text and Data Mining valid from 2022-01-25

Version of Record valid from 2022-01-25
More Information

Article History

Received: 26 September 2021

Accepted: 6 December 2021

First Online: 25 January 2022

Declarations

:

: The authors declare that they have no conflict of interest. Imusil is a patent registered product (file no: TEMP/E-1/61879/2021-MUM) of Glowderma Pvt. Ltd. Mumbai, India.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below